Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SciSparc Ltd. Ordinary Shares
SPRC | US
8.73
USD-1.86
-17.56%
SPRC | US
About SciSparc Ltd. Ordinary Shares
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/03/2024
As of date
02/06/2026
Close
8.73
Open
9.96
High
10.18
Low
8.70
SciSparc Ltd. a specialty clinical-stage pharmaceutical company develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome obstructive sleep apnea and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety tolerability and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. SciSparc Ltd. has collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. The company was incorporated in 2004 and is headquartered in Tel Aviv-Yafo Israel.
View LessSPRC | US
Risk
508.7
Sharpe
0.03
Luna's Score
42/100
Recommendation
Sell
Luna says (SPRC | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
723.7%1 month
508.7%3 months
329.5%6 months
243.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.31
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
1.21
Ent. to rev.
0.05
PEG
-
Other Fundamentals
EBITDA
-5.28M
MarketCap
90.42M
MarketCap(USD)
90.42M
Div. yield
-
Op. margin
-309.37
Erngs. growth
-
Rev. growth
-32.70
Ret. on equity
-73.37
Short ratio
0.51
Short perc.
8.03
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
11.65
Range1M
11.65
Range3M
15.18
Volumes: Market Activity
Rel. volume
0.08
Price X volume
1.22M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.21 | - | Expensive |
| Ent. to Revenue | 0.05 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.31 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 329.52 | - | Riskier |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 90.42M | - | Emerging |
